Human Isocitrate Dehydrogenase Gene Mutations PCR Kit

In the field of molecular biology and clinical diagnostics, the accurate detection of gene mutations has become a cornerstone for understanding disease mechanisms, guiding treatment decisions, and improving patient outcomes. Among the various genes linked to human diseases, the isocitrate dehydrogenase (IDH) gene family—specifically IDH2—plays a critical role in cellular metabolism and redox balance. Mutations in IDH2, particularly at the R140 and R172 amino acid positions, have been extensively associated with several hematological malignancies (such as acute myeloid leukemia, AML) and solid tumors (including cholangiocarcinoma and gliomas). These mutations lead to the production of an abnormal metabolite, 2-hydroxyglutarate (2-HG), which disrupts normal cell signaling and epigenetic regulation, driving tumorigenesis.

Against this backdrop, the demand for reliable, specific, and easy-to-use tools for detecting IDH2 mutations has grown exponentially. Traditional mutation detection methods, such as Sanger sequencing, while accurate, are often time-consuming (requiring multiple manual steps and long turnaround times), labor-intensive (needing skilled technical personnel), and less sensitive for low-abundance mutant alleles—limitations that hinder timely clinical decision-making and large-scale sample screening.

Polymerase Chain Reaction (PCR)-based assays have emerged as a game-changing solution to address these challenges. By leveraging the high specificity of PCR primer-probe systems and the efficiency of target amplification, PCR assay kits enable rapid and sensitive detection of specific gene mutations. Our Polymerase Chain Reaction (PCR) Assay Kit (Cat.No: PP-00118) is specifically designed to target the nine key IDH2 R140 and R172 mutations, filling a critical gap in the market for tools that combine accuracy with practicality for both research and clinical diagnostic applications.

Key drivers behind the development of this kit include:
The increasing need for early-stage disease detection: IDH2 mutations are often detected in pre-leukemic clones or early-stage tumors, making timely identification essential for proactive intervention.
The shift toward personalized medicine: Knowing a patient’s IDH2 mutation status helps clinicians select targeted therapies (e.g., IDH inhibitors) that are more effective and have fewer side effects compared to conventional treatments.
The demand for workflow efficiency: Clinical laboratories and research institutions require assays that integrate seamlessly into existing workflows, minimizing hands-on time and reducing the risk of human error.